{
    "score": [
        0.4444444444444444
    ],
    "extracted": [
        0
    ],
    "abstract": [
        "cancer genetics vs. davita head to head contrast ."
    ],
    "id": "228023.train",
    "article": [
        "cancer genetics and davita are both medical companies , but which is the better business ? we will compare the two businesses based on the strength of their analyst recommendations , valuation , profitability , risk , dividends , earnings and institutional ownership . analyst recommendationsthis is a summary of current ratings and target prices for cancer genetics and davita , as provided by marketbeat . com . sell ratingshold ratingsbuy ratingsstrong buy ratingsrating scorecancer genetics01302 .75 davita15322 .55 cancer genetics currently has a consensus target price of $ 6.00 , suggesting a potential upside of 207.69 % . davita has a consensus target price of $ 73.33 , suggesting a potential upside of 3.99 % . ",
        "given cancer genetics ' stronger consensus rating and higher possible upside , equities analysts plainly believe cancer genetics is more favorable than davita . institutional and insider ownership12 .7 % of cancer genetics shares are held by institutional investors . comparatively , 85.3 % of davita shares are held by institutional investors . 21.3 % of cancer genetics shares are held by company insiders . comparatively , 2.1 % of davita shares are held by company insiders . strong institutional ownership is an indication that endowments , hedge funds and large money managers believe a stock will outperform the market over the long term . ",
        "profitabilitythis table compares cancer genetics and davita 's net margins , return on equity and return on assets . net marginsreturn on equityreturn on assetscancer genetics-54.65 % -46.21 % -24.62 vita3 .40 .31 % 3.55 rnings & valuationthis table compares cancer genetics and davita 's gross revenue , earnings per share and valuation . gross revenueprice/sales rationet incomeearnings per shareprice/earnings ratiocancer genetics $ 27.05 million2 .00 - $ 15.80 million-2.01 davita $ 14.75 billion0 .88 $ 879.87 million $ 2.6027.12 davita has higher revenue and earnings than cancer genetics . cancer genetics is trading at a lower price-to-earnings ratio than davita , indicating that it is currently the more affordable of the two stocks . ",
        "volatility & riskcancer genetics has a beta of 1.11 , indicating that its stock price is 11 % more volatile than the s&p 500 . comparatively , davita has a beta of 0.97 , indicating that its stock price is 3 % less volatile than the s&p 500 . summarydavita beats cancer genetics on 8 of the 13 factors compared between the two stocks . about cancer geneticscancer genetics , inc. . is a united states-based company , which is engaged in the field of personalized medicine . the company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics . ",
        "the company offers a range of laboratory services that provide genomic and biomarker information . its select one clinical trials program provides a range of integrated and dynamic clinical trial services for both oncology and non-oncology genetic testing for phase i-iii trials along with ancillary services , including bioinformatics , biorepository and trials logistic support . the company is developing a global footprint with locations in the united states , india and china . it also offers a portfolio of genotyping services , with access to over 400 validated genotyping assays , including phase i and phase ii drug metabolizing enzymes , transporters , and receptors , and over 30 validated gene expression assays . ",
        "about davitadavita inc. , formerly davita healthcare partners inc. , operates two divisions : davita kidney care and davita medical group . the kidney care division consists of its the united states dialysis and related lab services , its ancillary services and strategic initiatives , including its international operations , and its corporate administrative support . its dmg division is a patient - and physician-focused integrated healthcare delivery and management company that provides medical services to members through capitation contracts . its segments include u. s. dialysis and related lab services , dmg , and other-ancillary services and strategic initiatives . ",
        "its u. s. dialysis and related lab services line of business provide kidney dialysis services in the united states for patients suffering from chronic kidney failure , also known as end stage renal disease . as of december 31 , 2016 , it had operated or provided administrative services to 154 outpatient dialysis centers . receive news & ratings for cancer genetics daily - enter your email address below to receive a concise daily summary of the latest news and analysts ' ratings for cancer genetics and related companies with marketbeat . com 's free daily email newsletter .  "
    ]
}